Quantcast

Bernstein Liebhard LLP Investigating Anatabloc Lawsuit Claims Against Manufacturers and Sellers of Dietary Supplement Purported to Treat Chronic and Incurable Medical Conditions

February 6, 2014

NEW YORK, Feb. 6, 2014 /PRNewswire/ — The nationwide law firm of Bernstein Liebhard LLP is now investigating Anatabloc lawsuit (http://www.consumerinjurylawyers.com/consumer-products/anatabloc-lawsuit/) claims against Star Scientific Inc. (NASDAQ: STSI), Rock Creek Pharmaceuticals, Inc. and GNC Holdings, Inc. (NYSE: GNC), the manufacturers and sellers of Anatabloc dietary supplements. Anatabloc was recently the subject of a warning letter issued by the U.S. Food & Drug Administration (FDA) that asserted claims regarding the ability of anatabine, a key ingredient the product, to treat certain chronic and incurable medical conditions were unfounded.

(Logo: http://photos.prnewswire.com/prnh/20120202/MM47134LOGO )

“Our Firm is eager to hear from any consumer who purchased Anatabloc dietary supplements. The allegedly misleading statements used by Star Scientific to promote the sale of this product may entitle those consumers to a refund of the purchase price, as well as other damages,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal evaluations to individuals who are interested in filing an Anatabloc lawsuit.

Anatabloc FDA Warning Letter

Anatabloc is manufactured by Star Scientific, a wholly-owned subsidiary of Rock Creek Pharmaceuticals, Inc. The product retails for $99.00 per bottle, and is available for sale at GNC, a nationwide chain of health and wellness stores. A key ingredient in Anatabloc is anatabine, which occurs naturally in cauliflower, eggplant, potatoes, and tomatoes,

On December 20, 2013, the FDA issued a warning letter to Star Scientific which took issue with statements made by the company regarding anatabine’s anti-inflammatory properties, specifically its purported ability to mitigate inflammatory bowel disease, ulcerative colitis, Crohn’s disease and traumatic brain injury. The FDA warning letter also characterized anatabine as a new drug that requires approval by the FDA.

On December 31, the FDA released a Consumer Alert that specifically noted the warning letter issued to Star Scientific. The purpose of the Alert was to caution the public about companies which offer untested, unproven and possibly dangerous products that claim to prevent, treat or cure concussions and other traumatic brain injuries. According to the agency, these products are not backed by scientific evidence that proves they are safe or effective for such purposes.

Consumers who purchased Anatabloc dietary supplements may be entitled to compensation from the manufacturers and sellers of this product. To learn more about filing an Anatabloc lawsuit, please visit Bernstein Liebhard LLP’s website. To obtain a free review of your case, please call (888) 340-4807.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(888) 340-4807

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (888) 340-4807. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Christian Siebott
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
www.consumerinjurylawyers.com
https://plus.google.com/115936073311125306742?rel=author

SOURCE Bernstein Liebhard LLP


Source: PR Newswire



comments powered by Disqus